Day-1    Afternoon Session

Symposium on: "Accelerating Drug Discovery and Development Through Academic Collaborations"

Chairman : Thomas D.Y. Chung, PH.D

Thomas D.Y. Chung, Ph.D.
Director, Translational Programs Outreach, SBP Medical Discovery Institute, CA USA
Title: Accelerating Translational Research into Drug Discovery in Academia through Strategic Partnerships
Stephanie C. Oestreich, MPA
EVP, Head BRIDGEs Partnerships North America, Evotec
Title: Bridging the Drug Discovery Gap
Jadwiga Bienkowska, Ph.D.
Oncology Translational Research, Pfizer, ORD, San Diego, CA, USA
Title: Watson Analytics: AI Research Assistant for Drug Discovery in Oncology
Dean G. Brown, Ph.D.
Director of External Chemistry, Hit Discovery, Discovery Sciences IMED Biotech Unit, AstraZeneca, MA, USA
Title: The use of an open innovation discovery model at AstraZeneca to access novel targets
Michelle Arkin, Ph.D.
Co-director, Small Molecule Discovery Center (SMDC), San Francisco, CA, USA
Title: A Consortium-Based Approach to Academic Drug Discovery
Christine Brideau, Ph.D.
Vice President, In Vitro Biology, Research Service Division (RSD), WuXi AppTec, NJ, USA
Title: Perspectives on building effective partnerships between CROs and Academia
Anuradha Roy, Ph.D.
Director, High Throughput Screening Laboratory
University of Kansas, KS, USA
Title: Early Drug Discovery in Academia
Whitney Smith, Ph.D.
Director, Business Development,
Collaborative Drug Discovery Inc., CA, USA
Title: Lessons Learned While Deploying Present and Developing Future Collaborative Informatics Innovations

Day-2    Morning Session

Symposium on: "Target Validation and Lead Optimization"

Co-Chairman : Christine Brideau, PH.D   RYAN BENNETT, PH.D

Ryan Bennett, Ph.D.
Chief Scientific Officer, OyaGen, Inc., Rochester NY, USA
Title: Drug Development Utilizing Targets within an Interactome
Howard Maibach, M.D.
Professor, UCSF School of Medicine, San Francisco, CA, USA
Title: Innovation from Academic Dermatology
Weian Zhao, Ph.D.
Sue and Bill Gross Stem Cell Research Center
University of California, Irvine, CA, USA
Title: Targeting Biophysical Cues to Study, Diagnose, and Treat Cancer
Thomas Webster, Ph.D.
Northeastern University, MA, USA
Title: Antibiotic resistant bacteria, chemotherapeutic resistant cancer cells: Conventional drug therapy needs a nano face lift
Adam R. Renslo, Ph.D.
Director of Chemistry, University of California, San Francisco, CA, USA
Title: Ferrous Iron Dependent Pharmacology in Cancer and Infectious Disease
Jikui Song, Ph.D.
University of California, Riverside
Title: Perspectives for Zika Virus NS5 Protein as a Drug Target
Harris Andrew Gelbard, Ph.D.
University of Rochester School of Medicine and Dentisty, NY, USA
Title: Broad-spectrum Mixed Lineage Kinase Inhibition for Treatment of Multiple End Organ Diseases with Inflammation

Day-2    Afternoon Session

Symposium on: "RNA as a Drug, Drug Target and Gene Editing Tool in Target Validation"

Co-Chairman : Troels Koch, M.Sc, Ph.D   Ailong Ke, Ph.D

Elliott Nickbarg, Ph.D.
Merck Research Laboratories, Boston, MA, USA
Title: Investigating Non-coding RNAs as Small Molecule Drug Targets using Afinity-Selection Mass Spectrometry
Dirk Daelemans, Ph.D.
KU Leuven, Rega Institute
Title: Target deconvolution of small-molecules by CRISPR/Cas-mediated resistance mutagenesis scanning
Susana Valente, Ph.D.
Department of Immunology and Microbiology, The Scripps Research Institute, FL, USA
Title: Silencing of the HIV Reservoir with a Potent Tat Inhibitor
Ailong Ke, Ph.D.
Department of Molecular Biology and Genetics, Cornell University, NY, USA
Title: Structure,mechanism, and potential applications of the Type I CRISPR-Cas system
Rocco G. Gogliotti, Ph.D.
Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, TN, USA
Title: Cross-species expression profiling for improved target selection in Rett syndrome
Hashim M Al-Hashi, Ph.D.
Director, Duke Center for RNA Biology, Duke University, NC, USA
Title: Dynamic Ensemble-based Discovery of Small Molecules Targeting RNA

Day-3    Morning Session

Symposium on: "Drug Target Discovery in Rare Diseases"

Co-Chairman : WENDY CORNELL, PH.D   Paul C. Trippier, PH.D

Paul C. Trippier, Ph.D.
Texas Tech University Health Sciences Center, TX, USA
Title: Multi-modal Small Molecule Therapeutic Development for Batten Disease
Juergen Lademann, Ph.D.
Professor of Dermatology, Head - CCP, Berlin, Germany
Title: Drug Delivery with Nanoparticles – Science Fiction or Reality
Jennifer E. Golden, Ph.D.
University of Wisconsin-Madison, WI, USA
Title: Design and Development of First-In-Class Encephalitic Alphavirus Inhibitors with Prophylactic and Therapeutic In Vivo Efficacy
Paul S. Brookes, Ph.D.
University of Rochester School of Medicine and Dentistry, NY, USA
Title: Role of Mitochondrial Complex II in Cardiac Ischemia, and Optimizing its Inhibition for Therapeutic Benefit
Hamid Mirzaei, Ph.D.
UT Southwestern Medical Center
Title: Hydralazine: A FDA Approved Drug with Multiple Therapeutic Targets
Sunil Premawansa, Ph.D.
University of Colombo
Sri Lanka
Title: Involvement of Angiopoietin 1 and 2 in dengue patients specifically with respect to critical stage of dengue haemorrhagic fever
Johannes Reynisson, Ph.D.
School of Chemical Sciences, University of Auckland, New Zealand
Title: Virtual Screening for Novel Atg5-Atg16 Complex Inhibitors for Autophagy Modulation

Join Our Newsletter